Compare ARVN & FPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | FPI |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 516.2M | 503.5M |
| IPO Year | 2018 | 2013 |
| Metric | ARVN | FPI |
|---|---|---|
| Price | $8.10 | $9.68 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 19 | 1 |
| Target Price | ★ $15.05 | N/A |
| AVG Volume (30 Days) | ★ 685.8K | 466.4K |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.14% |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $262,600,000.00 | $52,178,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $985.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.06 | $9.37 |
| 52 Week High | $14.22 | $13.23 |
| Indicator | ARVN | FPI |
|---|---|---|
| Relative Strength Index (RSI) | 46.57 | 45.92 |
| Support Level | N/A | $9.45 |
| Resistance Level | $8.90 | $10.59 |
| Average True Range (ATR) | 0.38 | 0.17 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 22.00 | 46.93 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.